Mrc375 150mg (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
46 | Malignant rheumatoid arthritis | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01408602 (ClinicalTrials.gov) | November 2011 | 2/8/2011 | A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients | A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: MRC375;Drug: Matching Placebo;Drug: MRC375 150mg | Molecular Research Center, Inc. | Camargo Pharmaceutical Services;Clin Data Services;Harrison Clinical Research;BARC Global Central Laboratory;Bilcare Global Clinical Supplies | Active, not recruiting | 18 Years | N/A | Both | 300 | Phase 2 | United States |